*Blanca R. Del Pozzo-Magaña,1 Alejandro Lazo-Langner2,3
1. Department of Pediatrics, University of Western Ontario, Ontario, Canada
2. Department of Medicine, Division of Hematology, University of Western Ontario, Ontario, Canada
3. Department of Epidemiology and Biostatistics, University of Western Ontario, Ontario, Canada
*Correspondence to firstname.lastname@example.org
Disclosure: The authors have declared no conflicts of interest.
Received: 30.06.16 Accepted: 13.10.16
Citation: EMJ Dermatol. 2016;4:83-89.
Stevens-Johnson syndrome and toxic epidermal necrolysis are among the most concerning drug reactions affecting adults and children. Although the overall mortality has reduced substantially after the introduction of several strategies, such as prompt withdrawal of the causal drug and management of the patients in an intensive care or burn unit, these conditions continue to be associated with severe complications and a mortality rate of 1–4%. Currently, several treatment options including systemic corticosteroids, intravenous immunoglobulins, cyclosporine, tumour necrosis factor-α inhibitors, and plasmapheresis among others, have shown inconclusive benefits regarding their efficacy and safety in patients with these conditions. This review analyses the most recent literature regarding treatment options for paediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.